Diabetes, SGLT-2 Inhibitors

• Diabetes, SGLT-2 Inhibitors - Feb 06, 2025
• Diabetes, SGLT-2 Inhibitors - Oct 05, 2023
• GLP-1 Receptor Agonists and SGLT-2 Inhibitors - Oct 06, 2022
• SGLT-2 Inhibitors Class Update - Aug 05, 2021
• Newer Diabetes Drugs - Aug 06, 2020
• Newer Diabetes Treatments - Jul 26, 2018
• Diabetes Class Update - Sep 28, 2017
• Newer Diabetes Medications and Combinations - Sep 29, 2016
• Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors - Mar 31, 2016
• Diabetes mellitus - Sep 24, 2015

• July 2023 - Update on the Use of SGLT-2 Inhibitors
• September 2020 - Cardiovascular Outcomes Associated with Newer Therapy Classes for Type 2 Diabetes Mellitus
• January 2019 - 2017-18 Year in Review: Important Safety Updates
• November 2017 - Marketing Claims of Newer Drugs and the Evidence
• March 2016 - Antidiabetic Treatments and Cardiovascular Implications
• February 2016 - 2015 in Review: Relevant Safety Updates and Ongoing Safety Concerns

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.